BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 11489837)

  • 1. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
    Tortora G; Bianco R; Damiano V; Fontanini G; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Jun; 6(6):2506-12. PubMed ID: 10873106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
    Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
    Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
    Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
    Tortora G; Caputo R; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Ciardiello F
    Clin Cancer Res; 1999 Apr; 5(4):875-81. PubMed ID: 10213224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
    Nesterova MV; Cho-Chung YS
    Clin Cancer Res; 2004 Jul; 10(13):4568-77. PubMed ID: 15240549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
    Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O; Hacker NF; Cho-Chung YS
    Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
    Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG
    Cancer Res; 2003 Feb; 63(3):593-9. PubMed ID: 12566301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.